Provectus Biopharmaceuticals, INC Form 4 insider transactions

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc., filed an SEC Form 4 detailing changes in beneficial ownership, including a correction to previously reported Series D-1 Convertible Preferred Stock.

Dominic Rodrigues, Director and President of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), reported a transaction involving Series D-1 Convertible Preferred Stock.

John Lacey III reports a conversion of Series D-1 Convertible Preferred Stock into Common Stock at Provectus Biopharmaceuticals, Inc.

Director Bailey Webster reports a conversion of Series D-1 Convertible Preferred Stock into Common Stock.

CEO Edward Pershing converted an 8% unsecured convertible promissory note into 9,436 shares of Series D-1 Preferred Stock.

CEO Edward Pershing acquired a $15,000 8% unsecured convertible promissory note in Provectus Biopharmaceuticals.

Edward Pershing, CEO and Director of Provictus Pharmaceuticals, Inc., reported the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Edward Pershing, CEO and Director of Provictus Pharmaceuticals, Inc., reported a conversion of a convertible promissory note into Series D-1 Convertible Preferred Stock.

Edward Pershing, CEO of Provictus Pharmaceuticals, reports changes in beneficial ownership of convertible notes and preferred stock.

Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Edward Pershing, CEO and Director of Prov3ctus Biopharma, Inc., reported the conversion of an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an 8% unsecured convertible promissory note and beneficially owns Series D-1 Convertible Preferred Stock, increasing his indirect ownership.

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Preferred Stock, which then converted into common stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $35,000, convertible into Series D-1 Preferred Stock.

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an additional $20,000 in convertible notes, increasing his total beneficial ownership.

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an $15,000 8% unsecured convertible promissory note as part of the company's 2025 financing.

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock, which is convertible into common stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $50,000, convertible into Series D-1 Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $30,000, convertible into Series D-1 Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired 34,940 shares of Series D-1 Convertible Preferred Stock in a private transaction, convertible into 349,400 common shares.

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $10,000 as part of the company's 2025 financing.

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into 37,744 shares of Series D-1 Convertible Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an $15,000 convertible promissory note, signaling continued investment in the company.

Provectus Biopharmaceuticals CEO Edward Pershing converted an 8% unsecured convertible promissory note into common stock, increasing his direct ownership.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $45,000, convertible into Series D-1 Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $75,000, convertible into Series D-1 Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired a $70,000 convertible promissory note and disposed of 24,459 shares of Series D-1 Preferred Stock.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an $30,000 8% unsecured convertible promissory note, convertible into Series D-1 Preferred Stock.

Provectus Biopharmaceuticals' CEO, Edward Pershing, acquired an $30,000 convertible promissory note as part of the company's 2025 financing.

Provectus Biopharmaceuticals CEO Edward Pershing acquired an $35,000 convertible promissory note as part of the company's 2025 financing plan.